Bristol-Myers Squibb welcomes Dr. Manuel Hidalgo Medina to its Board of Directors

– USA, NY –  Bristol-Myers Squibb (NYSE: BMY) today announced the election of Dr. Manuel Hidalgo Medina, M.D., Ph.D., to its Board of Directors, effective June 1, 2021, increasing the Board to 11 members.

“We are delighted to welcome Manny to our Board of Directors,” said Board chair and CEO, Dr. Giovanni Caforio. “As an internationally-renowned physician, scientist and academic, Manny’s deep expertise in oncology and track record in leading research will help us deliver on our mission of developing new, transformational medicines that benefit patients with serious diseases, further progress our pipeline and advance our long-term strategy.”

Dr. Hidalgo will serve as a member of the Science & Technology Committee.

Theodore Samuels, lead independent director said, “We are pleased to welcome Manny to Bristol Myers Squibb’s Board. Manny’s career, spanning the fields of academia, medicine and cancer research, gives him great perspective on the emerging dynamics of oncology research and development. With his election, we have further strengthened our Board with additional clinical expertise, scientific insights and understanding of our patients’ needs.”

About Dr. Manuel Hidalgo Medina

Dr. Manuel Hidalgo Medina is currently chief of the division of hematology and medical oncology at Weill Cornell Medicine and New York-Presbyterian/Weill Cornell Medical Center where he is responsible for leading clinical and translational research in hematology, vascular biology and oncology. Dr. Hidalgo is also the E. Hugh Luckey distinguished professor of medicine and associate director for clinical services at the Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine.

He brings to the Board more than 20 years of experience in translational and clinical research in anticancer drug development with a particular emphasis in gastrointestinal cancers. He has also led the early clinical development of new anticancer agents for pancreatic cancer among other solid tumor cancers.

Prior to his current position, Dr. Hidalgo served as chief of the division of hematology at Beth Israel Deaconess Medical Center in Boston and as clinical director of the Rosenberg Clinical Cancer Center from 2015-2019. He also held the position of the Theodore W. and Evelyn G. Berenson Professor of Medicine at Harvard Medical School. Dr. Hidalgo also served in leadership positions at the Spanish National Cancer Research Centre (CNIO) in Madrid and at the Kimmel Comprehensive Cancer Center where he served as the director of gastrointestinal oncology program.

He received his medical degree from the University of Navarra in Pamplona, Spain, and a doctorate in infectious diseases and cancer from the University Autónoma of Madrid, Spain. He completed his residency training in medical oncology at the Hospital 12 de Octubre in Madrid and his fellowship in medical oncology at the University of Texas Health Science Center in San Antonio, where he also served as an assistant professor of medicine.

Dr. Hidalgo commented, “With its continued focus on science, Bristol Myers Squibb continues to innovate and develop a robust and diverse pipeline of therapies that have the potential to benefit patients around the world. I am honored to join the Board and look forward to working with Giovanni, my fellow directors and the leadership team to help advance the company’s strategy.”

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.

For more information, visit us at BMS.com

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.